改善患者合適性的給藥技術創新

改善患者合適性的給藥技術創新 是由出版商Business Insights在2011年07月所出版的。 這份英文市場調查報告書包含Pages: 147 價格從美金3835起跳。

簡介

本報告書內容包括:患者合適性不良的原因和其克服原因所使用的技術、開發中所放出調整口服投藥技術的概要等彙整、內容綱要摘記如下:

實施摘要

患者合適性

• 摘要
• 介紹
• 患者合適性的改善：給藥為焦點
• 投藥過程
• 患者合適性的未來展望

放出調整口服投藥技術

• 摘要
• 介紹
• 即時放出
• 即時放出傾向投藥平台
  • 口腔内瓦解錠
  • 口腔薄膜技術
  • 即時放出口服黏膜處方
• 持續放出
• 放出控制
  • 放出延遲處方
  • 脈衝放出處方
• 持續放出和放出控制的給藥平台
  • 離子交換樹脂系統
  • 塗裝技術
  • 擴散的聚合物技術或生體內分解性給藥系統
  • 浸透系統　其他
• 放出調整口服投藥的今後展望

放出調整非口服投藥技術

• 摘要
• 介紹
• 放出調整輸入劑
  • 懸吊
  • 微粒子放出持續系統
  • 脂質體及其他
  • 奈米粒子　其他
• 放出調整吸入劑
• 放出調整經鼻給藥
• 經皮投藥系統的進步
• 未來的展望

設備

• 摘要
• 介紹
• 口服設備
  • 口服電子機械系統
  • 磁氣給藥控制
• 輸入・內建設備
  • 預填充注射器
  • 自動注射、筆型注射器
  • 攜帶式輸入幫浦
  • 內建型輸入幫浦
  • 免打針輸入器
• 吸入設備
  • 噴霧器
  • 定量吸入器
  • 乾粉式吸入器
  • 其他設備
• 鼻腔設備
  • 液體噴霧、定量、乾粉分注器
  • 經鼻給藥設備的技術創新
• 皮膚設備
  • 皮膚貼布
  • 皮膚浸透促進設備
  • 微細針
  • 超音波
  • 皮膚消融
  • 電氣穿孔
• 未來的展望

附錄

圖表

目錄

Abstract

Introduction

This report gives in depth coverage of the factors driving patient non compliance. The report then goes on to describe and analyse key technologies being developed to improve compliance in the oral and parenteral delivery spaces. Finally the report looks at new delivery devices being developed which will improve patient compliance.

Features and benefits

• Understand the causes of poor patient compliance and the technologies that are already in use to overcome these causes.
• Assess key innovative modified release oral delivery technologies that are in development.
• Assess key innovative modified release parenteral technologies that are in development.
• Assess key innovative drug delivery devices that are in development and understand how they can improve patient compliance and for which indications.

Highlights

The importance of the oral route of administration from both a clinician and patient acceptance point of view means there has been a vast amount of development and research in drug delivery via this route. Noncompliance can be attributed to poor taste, difficulty in administration or swallowing, and the inconvenience of multiple doses per day.

Of all the modifications to parenteral delivery systems, the transdermal administration route is attracting the most attention. Across all parenteral delivery forms, the continued increase in the number of experimental protein and peptide drug candidates means that there is a high level of unmet need for delivery systems for these types of drugs.

Pharmaceutical devices will continue to drive patient compliance and acceptability as increased options make for a wider choice. The convergence of MEMS and nanotechnology with biological applications offers breakthrough in drug developments.

Your key questions answered

• What new technologies are being developed to improve patient compliance?
• Which companies are the leaders in the development of new delivery technologies aimed at improving compliance?
• What technologies in development can be applied to the specific therapy areas that my company is involved in?
• How will new technologies drive improvements in patient compliance?
• What new devices are in development that we could license to deliver our pipeline products?

Table of Contents

About the author

• Disclaimer

EXECUTIVE SUMMARY

• Patient compliance
• Modified release oral delivery technologies
• Modified release parenteral formulations
• Devices

Patient compliance

• Summary
• Introduction
• Improving patient compliance: A focus on drug delivery

• The route of administration
  • Enteral routes of administration
  • Parenteral routes of administration

• Future outlook on patient compliance

Modified release oral delivery technologies

• Summary
• Introduction
• Rapid release formulations

• Delivery platforms for rapid-release oral formulations
  • Orally disintegrating tablets (ODTs)
  • Oral thin film (OTF) technology
  • Rapid-release oral transmucosal formulations

• Sustained-release formulations

• Controlled-release formulations
  • Delayed-release formulations
  • Pulsatile-release formulations

• Delivery platforms for sustained- and controlled-release
  • Ion-exchange resin systems
  • Coating technologies
  • Polymer technology for diffusion or bioerodible delivery systems
  • Osmotic systems
  • Reservoir diffusion systems
  • Liposomal delivery systems
  • Multiphase systems
  • Gastric retention systems
  • Transmucosal systems

• Future outlook for modified release oral formulations

Modified release parenteral formulations

• Summary
• Introduction

• Modified-release injectable formulations
  • Suspensions
  • Microparticulate sustained release systems
  • Liposomes and other vesicles
  • Solid lipid nanoparticles
  • Biodegradable depot or implant formulations
  • In situ gel systems
  • Non-biodegradable implants

• Modified-release inhaled formulations
  • Immediate release technologies
  • Sustained release technologies

• Modified release nasal delivery

• Advances in transdermal and cutaneous delivery systems
  • Modification of the drug or drug delivery vehicle
  • Modification of the stratum corneum

• Future outlook for modified release parenteral formulations

Devices

• Summary
• Introduction

• Oral devices
  • Oral micro-electro-mechanical systems (MEMS)
  • Magnetic delivery control

• Injectable and implantable devices
  • Prefilled syringes (PFS)
  • Auto-injectors & pen injectors
  • Solid dose injection
  • Portable infusion pumps
  • Implantable infusion pumps
  • Needle-free injections

• Inhalation devices
  • Nebulizers
  • Metered dose inhalers (MDIs)
  • Dry powder inhalers (DPIs)
  • Other novel inhalation devices

• Intranasal devices
  • Liquid spray, metered dose, and dry powder dispensers
  • Innovations in nasal delivery devices

• Transdermal devices
  • Transdermal patches
  • Transdermal penetration enhancement devices
  • Microneedles
  • Ultrasound (sonophoresis and phonophoresis)
  • Dermal ablation or poration
  • Electroporation

• Future outlook for pharmaceutical devices

Appendix

• Raisin system
• ID-Cap
• MagneTrace
• Glossary
• Bibliography

TABLES

• Table: Onset of action times based on route of administration
• Table: Comparison of orally disintegrating tablet formulations

FIGURES

• Figure: The five dimensions of adherence
• Figure: Toxic, therapeutic, and sub-therapeutic ranges of two hypothetical drugs
• Figure: Injectable routes of administration
• Figure: Standard burst release and sustained release delivery profiles
• Figure: Rapid release delivery profile
• Figure: Disintegration mechanism of superdisintegrant materials
• Figure: Acupac's range of dissolvable films
• Figure: Delayed release delivery profile
• Figure: Pulsatile release delivery profile
• Figure: SODAS microparticle
• Figure: Matrix diffusion system
• Figure: Bioerodible system
• Figure: DiffCORE technology
• Figure: Osmotic system
• Figure: OsmoCap-CAST system
• Figure: Reservoir diffusion system
• Figure: Liposome
• Figure: Accordion Pill
• Figure: MICRODUR microparticles
• Figure: Medusa nanogel depot system
• Figure: Solid microspheres
• Figure: DURIN biodegradable implants
• Figure: I-vation bioerodible implant
• Figure: SABER in situ gel system
• Figure: Atrigel in situ gel system
• Figure: IntelliCap device
• Figure: ePille device
• Figure: Intellidrug dental implant
• Figure: Oval Medical's range of auto-injector devices
• Figure: Glide SDI device
• Figure: OmniPod insulin management system
• Figure: JewelPUMP device
• Figure: h-Patch device
• Figure: DUROS osmotic pump implant
• Figure: Zeneo range of needle-free injection devices
• Figure: Lectrjet range of needle-free injection devices
• Figure: Mini-Ject auto-injection device
• Figure: Components of a pressurized metered dose inhaler
• Figure: Cross-section of the Respimat SoftMist metered dose inhaler
• Figure: Dreamboat range of dry powder inhalers
• Figure: MicroDose dry powder inhaler
• Figure: Optinose breath activated dry powder nasal device
• Figure: DirectHaler Nasal dry powder nasal device
• Figure: ViaNase electronic atomizer device
• Figure: SmartRelief iontophoresis patch device
• Figure: ActivaPatch iontophoresis patch device
• Figure: BD Soluvia microneedle prefilled injection device
• Figure: Solid and hollow microstructured transdermal system
• Figure: Microneedle pump device
• Figure: Bioerodible microneedle device
• Figure: ViaDor radiofrequency dermal ablation technology
• Figure: Prelude SkinPrep mechanical dermal ablation device
• Figure: Raisin system

相關商品